JPMorgan lowered the firm’s price target on Quest Diagnostics to $152 from $153 and keeps a Neutral rating on the shares ahead of the Q4 report. The analyst believes investors will be focused on five key areas when the labs report: volume trends, the impact of the Protecting Access to Medicare Act delay on 2024 margins, updates on recent acquisitions and strategy, and 2024 guidance and sequencing.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics and Fitbit announce collaboration to study wearable devices
- Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System
- Quest Diagnostics acquires assets of Steward Health Care’s outreach lab services
- Quest Diagnostics unit, Alliance Foundation Trials enter collaboration
- Quest Diagnostics initiated with an Equal Weight at Barclays
